BUSINESS INSIGHTS

Xeris Pharmaceuticals Strengthens Its Patent Estate

XERIS PHARMACEUTICALS, INC. | August 20, 2021

Xeris Pharmaceuticals Strengthens Its Patent Estate
Xeris Pharmaceuticals, Inc., a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has recently been granted three new patents relating to its formulation technology platforms. The U.S. Patent and Trademark Office granted U.S. Patent Nos. 10,987,399 and 11,020,403 to Xeris, and the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 to Xeris. The US ‘399 patent covers storage-stable formulations of pramlintide, and the US ‘403 patent covers storage-stable formulations of benzodiazepines, both using Xeris’ proprietary XeriSol™ formulation technology. The Chinese ’185.5 patent covers pre-filled syringes containing a variety of active pharmaceutical ingredients, using Xeris’ proprietary XeriJect™ technology. These patents, and related patent applications that are pending in these and other patent offices around the world, also cover the uses of such products in treating a variety of diseases and disorders including diabetes.

“Our strategy as a platform company is to patent early and often to continue to strengthen our position as a product development and formulation company. These new patent grants represent a significant expansion of Xeris’ intellectual property portfolio and help us to continue to invest in our innovation into life-saving therapies that can benefit patients worldwide,” said Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals. “With the recent opening of our Research & Development center in Chicago, led by our Chief Scientific Officer and Xeris co-founder Dr. Steve Prestrelski, we anticipate that we will continue to develop and bring to the market novel solutions for treating and preventing a variety of human diseases and disorders, improving the quality of life for our patients and their families.”

The granting of these patents expands the size of Xeris growing patent portfolio, bringing the total number of patents granted to Xeris worldwide to 121 (16 of which have been granted in the US). In addition to these new patent grants, Xeris has 120 patent applications pending worldwide, and expects to receive patent grants on several of those pending applications within the next several months. These patent grants, which provide Xeris the right to exclude others from making, selling, and using its proprietary technologies, will provide patent protection to Xeris on its proprietary pharmaceutical products for at least the next decade. All patents are owned by Xeris.

About Xeris Pharmaceuticals, Inc.
Xeris is a pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world. With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable drug products, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke® in the U.S. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.

Spotlight

With the prevalence of asthma and chronic obstructive pulmonary disease (COPD) growing worldwide, the availability of primary human cells from these respiratory diseases is critical to increasing research and knowledge about the disease at a cellular level. In this study, we sought to identify genes differentially regulated in asthma and COPD lung fibroblasts (DHLF-asthma and DHLF-COPD).

Related News

RESEARCH

XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform

Excelra Knowledge Solutions Pvt Ltd | January 19, 2022

Excelra, a leading global Data & Analytics organization, announced the partnership for its Global Online Structure Activity Relationship Database with XtalPi Inc., an AI-based pharmaceutical biotechnology company reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform. Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. as part of the partnership. GOSTAR's ADMET data will power XtalPi's predictive models. The data helps XtalPi with high precision and predictability to confidently tackle clinical failures of new chemical entities. The well-annotated, high-quality ADMET datasets of GOSTAR are built with a proprietary QMS-ISO certified curation process powered by NLP and human intelligence. GOSTAR provides comprehensive information encompassing over 8 million compounds, manually curated from a variety of sources including patents and journal articles. The database contains over 29 million SAR associated data points. The well-structured relational database can be utilized for diverse applications across various stages of drug discovery and development lifecycle and aids in target validation, hit identification, early lead identification, and optimization. "In XtalPi Inc., we develop advanced AI-based algorithms to tackle the challenges in the drug design process. The size and quality of datasets are always a big concern for us to build high-accuracy predictive models. That is why we consider GOSTAR as a unique and precious resource. It has millions of data points covering different compounds' ADMET properties and is also trustful, structured, and updated. We highly recommend GOSTAR to whoever is involved in the innovation of drug design methodologies." Min Xu, Senior Scientist, Research Manager, XtalPi Inc Norman Azoulay, Product Leader, Excelra, said, "Artificial Intelligence and Machine Learning is bringing a paradigm shift to drug discovery and development. This partnership will help train XtalPi's models to accurately predict efficacy and safety parameters and to ultimately increase the success rate of drug design." About XtalPi XtalPi is a pharmaceutical technology company that is reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform. With tightly interwoven quantum physics, artificial intelligence, and high-performance cloud computing algorithms, XtalPi's platform provides accurate predictions on the physiochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. XtalPi is dedicated to improving the efficiency, accuracy, and success rate of drug research and development, and contributing to a healthier society worldwide. About Excelra Excelra's data and analytics solutions empower innovation in life sciences from molecule to market. The Excelra Edge comes from harmonizing heterogeneous data sets, applying innovative bioinformatics know-how and technologies to accelerate your drug discovery & development with reliable and result-oriented insights. Excelra's GOSTAR is available as an application for users to seek, find, and discover compounds. In addition, it is offered via APIs and as a downloadable dataset to power in-house libraries and machine learning models.

Read More

CPD AND LEARNING

PostEra and NeuroLucent Partners on identifying small-molecule therapeutics for Alzheimer's disease

PostEra | November 27, 2020

PostEra, a biotechnology organization offering restorative science fueled by AI, today reported a joint effort with NeuroLucent, a Chicago-put together organization centered with respect to creating novel medicines for Alzheimer's sickness and different dementias. The disappointment of late-stage clinical preliminaries to reveal viable treatments for Alzheimer's illness has underscored the need to investigate novel helpful methodologies. NeuroLucent is creating novel little atom aggravates that standardize a key calcium direct that is dysregulated in Alzheimer's neurons and reestablish ordinary neuronal capacity in different preclinical Alzheimer's models. NeuroLucent has collaborated with PostEra to quicken its quest for a helpful up-and-comer. PostEra will utilize its AI innovation to upgrade NeuroLucent's lead mixes through a progression of 'plan make-test' cycles that has recently been appeared to quicken therapeutic science crusades. PostEra will likewise use its Manifold stage, which gives admittance to mixes through an overall organization of merchants and accomplice contract research associations. Business terms incorporate a forthright installment to PostEra, with extra installments upon the accomplishment of specific achievements. "We're excited about the potential of integrating PostEra's technology into the design of more potent compounds," said Bill Kohlbrenner, CEO of NeuroLucent. "We are intrigued by PostEra's machine learning algorithm since it doesn't require detailed structural information related to the drug target. We're looking forward to seeing what impact PostEra's AI solutions will have on our program." About NeuroLucent NeuroLucent holds an exclusive license to technology developed at the Rosalind Franklin University of Medicine and Science by Dr. Grace (Beth) Stutzmann, who uncovered a link between aberrant Ca2+ signalling, long known to occur in Alzheimer's neurons, and a Ca2+ channel that becomes 'leaky' in disease. NeuroLucent's preclinical stage compounds have been validated in multiple disease models and the current company focus is on identifying a clinical development candidate that addresses the cognitive loss associated with Alzheimer's disease.

Read More

PHARMACY MARKET

NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies

NRx Pharmaceuticals | August 26, 2021

NRx Pharmaceuticals announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential Emergency Use Authorization (EUA) approval by the US Food and Drug Administration (FDA). In May, NRx submitted an application for EUA to the FDA for ZYESAMI™ (aviptadil) for patients suffering from Critical COVID-19 with respiratory failure. "This partnership creates an efficient and highly flexible logistics and distribution model for NRx. Cardinal Health's expertise will enable ZYESAMI to quickly reach patients in the intensive care units, as limiting the time to treatment is crucial," said Robert Besthof, Head of Operations and Chief Commercial Officer of NRx. "This also allows NRx to continue focusing on answering requests from the FDA in support of our application for Emergency Use Authorization for ZYESAMI." Cardinal Health Specialty Pharmaceutical Distribution will serve as the exclusive distributor for ZYESAMI, providing broad access to hospitals for this needed medicine upon FDA authorization. With one of the largest healthcare supply chains, Cardinal Health services more than 90% of hospitals in the U.S., and has more than 20 years of experience supporting rapid delivery of lifesaving medicines. Additionally, Cardinal Health's Third-Party Logistics Services (3PL) will support the warehousing and distribution, full order to cash, and necessary title model services. "As the COVID-19 pandemic continues, so does the need for more innovative, effective and FDA-approved therapies for critically-ill patients with respiratory failure," said Marc DeLorenzo, Senior Vice President of Strategic Sourcing at Cardinal Health. "Cardinal Health is pleased to ensure that COVID-19 patients get access to treatment in a timely and efficient manner." About NRx Pharmaceuticals NRx Pharmaceuticals draws upon more than 300 years of collective, scientific and drug-development experience to bring improved health to patients. Its investigational product, ZYESAMI™ (aviptadil) for patients with COVID-19, has been granted Fast Track designation by the US Food and Drug Administration (FDA) and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority part of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense. The FDA has additionally granted Breakthrough Therapy Designation, a Special Protocol Agreement, and a Biomarker Letter of Support to NRx for NRX-101, an investigational medicine to treat suicidal bipolar depression. NRX-101 is currently in Phase 3 trials, with readouts expected in 2022. In July 2021, NRx was awarded an exclusive worldwide license to develop and commercialize the BriLife (VSV-ΔG) COVID-19 vaccine developed by the Israel Institute of Biological Research. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.

Read More

Spotlight

With the prevalence of asthma and chronic obstructive pulmonary disease (COPD) growing worldwide, the availability of primary human cells from these respiratory diseases is critical to increasing research and knowledge about the disease at a cellular level. In this study, we sought to identify genes differentially regulated in asthma and COPD lung fibroblasts (DHLF-asthma and DHLF-COPD).